Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
Date:6/2/2008

var s=s_gi(s_account); var hd1 = document.getElementById('headline'); s.tl(this,'o',getLinkName('Company Sanpshot'));" >AEZS; TSX: AEZ) in the United States, Canada and Mexico.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, or ESRD. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also has an in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for KRX-0401, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward- looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully c
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
2. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
3. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
4. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
5. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
6. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
7. IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
8. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
9. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
10. Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer
11. Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 26, 2014 / -- China Nepstar Chain Drugstore Ltd. (NYSE: ... drugstore chain in China based ... the appointment of Ms. Rebecca Yingnan Zhang ... Ms.Zhang has over 20 years of experience ... 1999. Prior to Ms. Zhang,s appointment as the Company,s ...
(Date:11/24/2014)... , Nov. 24, 2014 Juno Therapeutics ... Therapy Designation to the company,s JCAR015 chimeric antigen ... treatment of relapsed or refractory B-cell acute lymphoblastic ... Memorial Sloan Kettering Cancer Center, where Phase 1 ... "The FDA,s action is important news for patients ...
(Date:11/24/2014)... , Nov. 24, 2014  Relmada Therapeutics, Inc. (OTCQB: ... treatment of chronic pain, announced today that Sergio ... at the LD MICRO "MAIN Event" Micro-Cap Growth Conference ... held at the Luxe Sunset Bel Air Hotel, which ... Los Angeles, California . The presentation ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer 2China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer 3Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 3Relmada Therapeutics To Present At LD MICRO Conference 2
... Sciences Holdings, Inc. (OTC Bulletin Board: ADLS) announced today ... the majority that Restanza(TM) (cethromycin) demonstrated safety for ... pneumonia (CAP) (11 positive, 3 negative, 1 abstaining). ... efficacy in the treatment of CAP (3 positive, 11 ...
... June 2 PharmAthene, Inc. (NYSE Amex: ... countermeasures against biological and chemical threats, today announced ... Biomedical Advanced Research and Development Authority (BARDA) in ... advanced research and development of medical countermeasures for ...
Cached Medicine Technology:Advanced Life Sciences Announces Outcome of FDA's Anti-Infective Drugs Advisory Committee Review of Restanza(TM) (cethromycin) 2Advanced Life Sciences Announces Outcome of FDA's Anti-Infective Drugs Advisory Committee Review of Restanza(TM) (cethromycin) 3PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R) 2PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R) 3PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R) 4PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R) 5
(Date:11/26/2014)... Medical suction and vacuum products have ... This score represents steady growth in the price of ... as a result of swelling demand for healthcare services ... largely considered nondiscretionary. IBISWorld market research analyst, Anna Son, ... degree of flexibility, given the low level of price ...
(Date:11/26/2014)... Rouge, Louisiana (PRWEB) November 26, 2014 ... neck pain relief and specialists in minimally invasive ... K. Samer Shamieh into the rapidly growing provider ... specialists. The addition coincides with the network’s ... reliable medical treatment for Louisiana residents who are ...
(Date:11/26/2014)... November 26, 2014 One of the ... at some point in her life is choosing the ... excellent platform for ladies to purchase high quality outfits. ... bridesmaid dresses. People now can pick their suitable bridesmaid ... chic dresses always make ladies look scintillating and highlight ...
(Date:11/26/2014)... Teens prescribed anti-anxiety or sleep medications are much ... teens, a new study warns. The findings ... on teenagers before prescribing these drugs to them, ... realize the abuse potential," said lead researcher Carol ... School of Nursing. "These drugs produce highly attractive ...
(Date:11/26/2014)... HealthDay Reporter TUESDAY, Nov. 25, 2014 (HealthDay ... and Drug Administration will have many restaurant chains posting calorie ... movie theater popcorn and ice cream parlor fare. "Americans ... often consuming less nutritious food and underestimating the calories they ... afternoon news conference. Although listing calorie counts on ...
Breaking Medicine News(10 mins):Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 4Health News:Louisiana Back Institute Welcomes Dr. K. Samer Shamieh into Medical Provider Network 2Health News:Royal Blue Bridesmaid Dresses Now Are Available for Christmas at BellasDress.com 2Health News:Teens Given Anxiety, Sleep Meds May Be at Risk for Drug Abuse 2Health News:Calorie Counts Mandated at Chain Restaurants, FDA Says 2Health News:Calorie Counts Mandated at Chain Restaurants, FDA Says 3
... Novel HIV Drug to be Studied in Cell ... A $6 million, five-year federal grant to The ... to investigate a novel approach in treating HIV infection ... therapies for psychological and neurological effects in AIDS. ...
... to concerns that the human papillomavirus vaccine might promote ... found that the majority of respondents did not believe ... infections. The study, conducted by University of Illinois ... and in the November issue of the Journal ...
... utter words , THURSDAY, Oct. 15 (HealthDay News) -- ... how the human brain computes language. , "Two central ... study: one, the way in which higher cognitive processes ... two, the nature of what is perhaps the best-known ...
... to curtail secondhand smoke, experts say , , THURSDAY, Oct. ... really do work at reducing heart attacks from secondhand smoke, ... the risk of heart attack by up to 47 ... according to a report released Thursday by the U.S. Institute ...
... ... the life science, engineering and entertainment industries, announced today they have signed an intellectual ... incorporating Microsoft’s SenseCam technology worldwide. , ... Oxford UK (PRWeb UK) October 15, 2009 -- Vicon, developer of ...
... , NEW YORK, Oct. 15 The Nielsen Company ... CLIO Awards , one of the world,s most recognized international advertising ... "The Dr. Oz Show" and featured health expert ... Honorary CLIO Healthcare Award live at the first-ever CLIO Healthcare ...
Cached Medicine News:Health News:NeuroAIDS is Target of Federal Grant to Children's Hospital 2Health News:NeuroAIDS is Target of Federal Grant to Children's Hospital 3Health News:NeuroAIDS is Target of Federal Grant to Children's Hospital 4Health News:UIC study finds girls aware of HPV vaccine's benefits 2Health News:Brain Yields Up Clues to Language 2Health News:Smoking Bans Reduce Heart Attacks: Study 2Health News:Smoking Bans Reduce Heart Attacks: Study 3Health News:Vicon Signs License Agreement with Microsoft to Develop New Medical Technology 2Health News:Vicon Signs License Agreement with Microsoft to Develop New Medical Technology 3Health News:Dr. Oz, Host of 'The Dr. Oz Show,' to Accept Honorary CLIO Healthcare Award Live at Nielsen's First-Ever CLIO Healthcare Awards Mixer 2Health News:Dr. Oz, Host of 'The Dr. Oz Show,' to Accept Honorary CLIO Healthcare Award Live at Nielsen's First-Ever CLIO Healthcare Awards Mixer 3